Topline data were announced from a #Phase3Trial demonstrating ONS-5010 (#BevacizumabVikg) was noninferior to #Ranibizumab at week 12 for the treatment of neovascular age-related macular degeneration (#WetAMD). 

Read more:#ONS5010 #ClinicalTrial #NORSEEightTrial #Optometry
#Phase3Trial #BevacizumabVikg #Ranibizumab #WetAMD #ONS5010 #ClinicalTrial